Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 68788-7700

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 68788-7700). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel Tab. Usp, 75mg

Label for Clopidogrel bisulfate 75 mg film-coated tablets from Preferred Pharmaceuticals, Inc. The label includes the proprietary name Clopidogrel Tab. USP 75 mg, mentions it is generic for Plavix, and states the active ingredient strength as 97.875 mg of clopidogrel bisulfate USP equivalent to 75 mg clopidogrel base. Manufacturer listed as ScieGen Pharmaceuticals, Inc. Warning and storage instructions are printed, along with barcode and QR code. The label is predominantly yellow with black and blue text.*

FDA Label Image

Clopidogrel Tablet Usp 75mg (Clopidogrel 75mg 30tab)

Clopidogrel 75 mg tablets, USP label for oral use. The film-coated tablets package contains 30 tablets. The label includes prescribing and storage information, notes it is Rx only, and lists the manufacturer as ScieGen Pharmaceuticals, Inc. The label also shows the NDC 50228-124-30 and a barcode.*

FDA Label Image

Clopidogrel 75mg 90tab

Label for Clopidogrel Tablets, USP 75 mg film-coated tablets by ScieGen Pharmaceuticals, Inc. The label indicates each tablet contains 97.875 mg clopidogrel bisulfate equivalent to 75 mg clopidogrel base. It is for prescription use, with a package size of 90 tablets. Storage instructions and pharmacist dispensing guidance are included.*

FDA Label Image

Figure1 (Clopidogrel Fig)

A chart showing the effect of multiple doses of Clopidogrel 75 mg alone or combined with four different proton pump inhibitors (PPIs): Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg. The horizontal axis represents change in active metabolite AUC relative to clopidogrel alone, with values ranging approximately from 0.4 to 1.4, including mean and 90% confidence intervals for each PPI co-administration.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

A line graph showing cumulative event rates (%) for cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares two groups: placebo plus aspirin and clopidogrel plus aspirin, indicating lower event rates in the clopidogrel group. The x-axis represents months of follow-up, and the y-axis represents cumulative event rate.*

FDA Label Image

Figure3 (Clopidogrel Fig3)

A forest plot chart comparing hazard ratios for Clopidogrel bisulfate versus placebo across various subgroups, including age, gender, race, diabetes, previous medical conditions, and concurrent medications. It shows the number and percentage of patients in each subgroup using Clopidogrel or placebo, with confidence intervals indicating the relative risk favoring Clopidogrel or placebo.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

A cumulative event rate line graph titled 'Figure 4: Cumulative Event Rates for Death in the COMMIT Study' showing percentage of deaths before first discharge over up to 28 days since randomization. The graph compares placebo and clopidogrel groups, with placebo at 8.1% deaths and clopidogrel at 7.5%, noting a 7% proportional risk reduction. A footnote states all treated patients received aspirin.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

A survival curve chart depicting the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. It compares placebo (10.1% event rate) with clopidogrel (9.2% event rate), indicating a 9% proportional risk reduction with clopidogrel (p=0.002).*

FDA Label Image

Figure6 (Clopidogrel Fig6)

Figure showing the effects of adding Clopidogrel to Aspirin on the combined primary endpoint across various baseline and concomitant medication subgroups from the COMMIT Study. The chart includes subgroup categories such as gender, age, hours since onset, systolic blood pressure (SBP), heart rate, and fibrinolytic agent given, with odds ratio plotted to compare Clopidogrel and placebo outcomes.*

FDA Label Image

Figure7 (Clopidogrel Fig7)

A line graph titled 'Fatal or Non-Fatal Vascular Events' showing cumulative event rate (%) on the vertical axis against months of follow-up on the horizontal axis, ranging from 0 to 36 months. Two lines are labeled Aspirin and Clopidogrel, depicting cumulative event rates over time, with Clopidogrel having a slightly lower event rate than Aspirin. A p-value of 0.045 is indicated on the graph.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

A forest plot labeled 'Figure 8: Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study' showing hazard ratios with 95% confidence intervals for stroke, MI, PAD subgroups, and overall. The plot compares Clopidogrel versus Aspirin effectiveness, with hazard ratio on the x-axis ranging from 0.6 to 1.3. Numerical values of event counts and percentages for Clopidogrel and Aspirin are displayed for each subgroup.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of clopidogrel bisulfate showing the molecular arrangement including a thiophene ring, a bicyclic ring system with nitrogen, and a chlorophenyl group, along with a sulfate component (H2SO4).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.